Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background Ipilimumab can induce durable disease control and long-term survival in patients with metastatic melanoma. Identification of a biomarker that correlates with clinical benefit and potentially provides an early marker of response is an active area of research.Patients and methods Ipilimumab was available upon physician request for patients aged ≥16 years with stage III (unresectable) or IV cutaneous, ocular or mucosal melanoma, who had failed or did not tolerate previous treatments and had no other therapeutic option available. Patients received ipilimumab 3 mg/kg every 3 weeks for four doses. Tumour assessments were conducted at baseline, Week 12 and Week 24 using immune-related response criteria. Patients were monitored continuously for adverse events (AEs), including immune-related AEs. Candidate immunological markers were evaluated in peripheral blood and sera samples collected at baseline and Weeks 4, 7, 10 and 12.Results Among 95 patients treated with ipilimumab 3 mg/kg, the immune-related disease control rate at Week 24 was 38 %. With a median follow-up of 24 months, median overall survival was 9.6 months. Both disease control and survival were significantly associated with decreasing levels of lactate dehydrogenase, C-reactive protein and FoxP3/regulatory T cells, and increasing absolute lymphocyte count, between baseline and the end of dosing (Week 12).Conclusion Ipilimumab is a feasible treatment option for heavily pretreated patients with metastatic melanoma. Changes in some immunological markers between baseline and the fourth ipilimumab infusion appear to be associated with disease control and survival, but verification in prospective clinical trials is required.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“increased lymphocyte counts in the blood are associated not only with favorable treatment outcome but also with increased overall survival in patients with melanoma treated with ICIs (132-135).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [133]
In the citing paper
“decreases in Tregs in the peripheral blood and tumors of patients with metastatic melanoma treated with ICIs have been associated with ICI response and increased patient survival”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [133]
In the citing paper
“Balatoni et al. (153) demonstrated that patients with melanoma who exhibited a higher frequency of Tregs in lymph node metastases responded better to ipilimumab compared with patients who had fewer Tregs (133).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [133]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 3×
“Ipilimumab, a monoclonal antibody against cytotoxic t-lymphocyte-associated antigen-4 (Ctla-4), was the first agent approved for the treatment of unresectable or metastatic (advanced) melanoma that showed an overall survival (OS) benefit in a randomised phase III trial [1].”
BackgroundImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationBiomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Korn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640
Self-citationHamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534 · cited 3×
“taking this into consideration, it was hypothesised that tregs, and thus FoxP3, may be upregulated in the tumours of patients with ongoing, yet suboptimal, antitumour immune responses and that these individuals may be more likely to respond to ipilimumab [20].”
Background
Cited by
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Heinhuis, K. M., Ros, W., Kok, M., Steeghs, N., Beijnen, J. H., & Schellens, J. H. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy551 · Cited by 557
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541
“This hypothesis is strongly supported by the observed correlation between decreasing levels of circulating Tregs during ipilimumab and favorable outcome (9).”
BackgroundSelf-citationPrimary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Gide, T. N., Wilmott, J. S., Scolyer, R. A., & Long, G. V. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2267 · Cited by 454
Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw016 · Cited by 395
Self-citationMénétrier-Caux, C., Ray-Coquard, I., Blay, J.-Y., & Caux, C. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0549-5 · Cited by 339
Biomarkers of response to PD-1/PD-L1 inhibition
Maleki Vareki, S., Garrigós, C., & Duran, I. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.06.001 · Cited by 318
Ferrucci, P. F., Gandini, S., Battaglia, A., Alfieri, S., Di Giacomo, A. M., Giannarelli, D., Cappellini, G. C. A., De Galitiis, F., Marchetti, P., Amato, G., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.180 · Cited by 262
Self-citationSong, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01956 · Cited by 261
Postow, M. A., Manuel, M., Wong, P., Yuan, J., Dong, Z., Liu, C., Perez, S., Tanneau, I., Noel, M., Courtier, A., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0070-4 · Cited by 232
“Increases in the absolute lymphocyte count and markers of activation such as inducible co-stimulator (ICOS) on CD4+ T cells have been shown to be pharmacodynamic biomarkers of ipilimumab that correlate with overall survival [3-7].”
BackgroundNovel technologies and emerging biomarkers for personalized cancer immunotherapy
Yuan, J., Hegde, P. S., Clynes, R., Foukas, P. G., Harari, A., Kleen, T. O., Kvistborg, P., Maccalli, C., Maecker, H. T., Page, D. B., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0107-3 · Cited by 229
Buder-Bakhaya, K., & Hassel, J. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01474 · Cited by 217
Lactate dehydrogenase: a marker of diminished antitumor immunity
Van Wilpe, S., Koornstra, R., Den Brok, M., De Groot, J. W., Blank, C., De Vries, J., Gerritsen, W., & Mehra, N. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1731942 · Cited by 208
Mucosal Melanoma: a Literature Review
Yde, S. S., Sjoegren, P., Heje, M., & Stolle, L. B. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0675-0 · Cited by 201
Limagne, E., Richard, C., Thibaudin, M., Fumet, J.-D., Truntzer, C., Lagrange, A., Favier, L., Coudert, B., & Ghiringhelli, F. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1564505 · Cited by 201
T cell pathology in skin inflammation
Sabat, R., Wolk, K., Loyal, L., Döcke, W.-D., & Ghoreschi, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00742-7 · Cited by 201
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R., Lesh, R. W., Ali, U., Kubiak, M., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 196
Dal Bello, M. G., Filiberti, R. A., Alama, A., Orengo, A. M., Mussap, M., Coco, S., Vanni, I., Boccardo, S., Rijavec, E., Genova, C., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1828-0 · Cited by 195
Fizazi, K., Drake, C. G., Beer, T. M., Kwon, E. D., Scher, H. I., Gerritsen, W. R., Bossi, A., den Eertwegh, A. J. M. V., Krainer, M., Houede, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.07.032 · Cited by 185
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00119 · Cited by 185
Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M. A., Wong, P., Capone, M., Madonna, G., Khammari, A., Schilling, B., Sucker, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0249 · Cited by 180
Self-citationHopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.274 · Cited by 180
Ascierto, P. A., Agarwala, S., Botti, G., Cesano, A., Ciliberto, G., Davies, M. A., Demaria, S., Dummer, R., Eggermont, A. M., Ferrone, S., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1070-y · Cited by 173
“In several cases, analysis of the excised tissue has revealed the presence of a diffuse immune infiltration which correlated with the outcome of these patients [78].”
BackgroundSelf-citationSuh, K. J., Kim, S. H., Kim, Y. J., Kim, M., Keam, B., Kim, T. M., Kim, D.-W., Heo, D. S., & Lee, J. S. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2092-x · Cited by 171
Biomarkers associated with checkpoint inhibitors
Manson, G., Norwood, J., Marabelle, A., Kohrt, H., & Houot, R. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw181 · Cited by 164
Brueckl, W. M., Ficker, J. H., & Zeitler, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07690-8 · Cited by 158
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
Luke, J. J., & Ott, P. A. (2015) · Oncotarget · doi:10.18632/oncotarget.2980 · Cited by 157
Zaragoza, J., Caille, A., Beneton, N., Bens, G., Christiann, F., Maillard, H., & Machet, L. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14155 · Cited by 150
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
Falcone, I., Conciatori, F., Bazzichetto, C., Ferretti, G., Cognetti, F., Ciuffreda, L., & Milella, M. (2020) · Cancers · doi:10.3390/cancers12102870 · Cited by 172
Soyano, A. E., Dholaria, B., Marin-Acevedo, J. A., Diehl, N. N., Hodge, D. O., Luo, Y., Manochakian, R., Chumsri, S., Adjei, A. A., Knutson, K. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0447-2 · Cited by 150
Rajan, A., Heery, C. R., Thomas, A., Mammen, A. L., Perry, S., Coyne, G. O., Guha, U., Berman, A. W., Szabo, E. M., Madan, R. A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0723-9 · Cited by 159
Biomarkers for Immunotherapy: Current Developments and Challenges
Spencer, K. R., Wang, J., Silk, A. W., Ganesan, S., Kaufman, H. L., & Mehnert, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_160766 · Cited by 162
D'Angelo, S. P., Shoushtari, A. N., Keohan, M. L., Dickson, M. A., Gounder, M. M., Chi, P., Loo, J. K., Gaffney, L., Schneider, L., Patel, Z., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2349 · Cited by 131
The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
van Dijk, N., Funt, S. A., Blank, C. U., Powles, T. B., Rosenberg, J. E., & van der Heijden, M. S. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.022 · Cited by 125
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Ziogas, D. C., Theocharopoulos, C., Koutouratsas, T., Haanen, J. B. A. G., & Gogas, H. J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102499 · Cited by 129
Basler, L., Gabryś, H. S., Hogan, S. A., Pavic, M., Bogowicz, M., Vuong, D., Tanadini‐Lang, S., Forster, R. E., Kudura, K., Huellner, M. W., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0020 · Cited by 126
Therapeutic use of anti-CTLA-4 antibodies
Blank, C. U., & Enk, A. (2015) · International Immunology · doi:10.1093/intimm/dxu076 · Cited by 115
Wistuba-Hamprecht, K., Martens, A., Heubach, F., Romano, E., Geukes Foppen, M., Yuan, J., Postow, M., Wong, P., Mallardo, D., Schilling, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.011 · Cited by 108
Self-citationRiedl, J. M., Barth, D. A., Brueckl, W. M., Zeitler, G., Foris, V., Mollnar, S., Stotz, M., Rossmann, C. H., Terbuch, A., Balić, M., et al. (2020) · Cancers · doi:10.3390/cancers12082319 · Cited by 115
Gide, T. N., da Silva, I. P., Quek, C. Y. J., Ahmed, T., Menzies, A. M., Carlino, M. S., Saw, R. P. M., Thompson, J. F., Batten, M., Long, G. V., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1659093 · Cited by 154
Colton, M., Cheadle, E. J., Honeychurch, J., & Illidge, T. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01678-1 · Cited by 98
C-reactive protein as an early marker of immune-related adverse events
Abolhassani, A.-R., Schuler, G., Kirchberger, M. C., & Heinzerling, L. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03002-1 · Cited by 107
Combination anti–PD-1 and antiretroviral therapy provides therapeutic benefit against SIV
Mylvaganam, G., Chea, L. S., Tharp, G. K., Hicks, S. L., Velu, V., Iyer, S. S., Deléage, C., Estes, J. D., Bosinger, S. E., Freeman, G. J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122940 · Cited by 92
Iivanainen, S., Ahvonen, J., Knuuttila, A., Tiainen, S., & Koivunen, J. P. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000531 · Cited by 106
Current status and perspectives in immunotherapy for metastatic melanoma
Marconcini, R., (IMI), F. T. I. M. I., Spagnolo, F., Stucci, L. S., Ribero, S., Marra, E., Rosa, F. D., Picasso, V., Guardo, L. D., Cimminiello, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23746 · Cited by 90
Self-citationBjoern, J., Nitschke, N. J., Iversen, T. Z., Schmidt, H., Fode, K., & Svane, I. M. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1100788 · Cited by 91
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
Mozzillo, N., Simeone, E., Benedetto, L., Curvietto, M., Giannarelli, D., Gentilcore, G., Camerlingo, R., Capone, M., Madonna, G., Festino, L., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008842 · Cited by 93
Self-citationBeyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
Voong, K. R., Feliciano, J. L., Becker, D. J., & Levy, B. P. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.48 · Cited by 90
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 84
Tarhini, A. A., & Kudchadkar, R. R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.005 · Cited by 87
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
Lü, Z., Peng, Z., Liu, C. X., Wang, Z., Wang, Y., Jiao, X., Li, J., & Shen, L. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100041 · Cited by 91
Inflammatory Markers in Cancer Immunotherapy
Ravindranathan, D., Master, V. A., & Bilen, M. A. (2021) · Biology · doi:10.3390/biology10040325 · Cited by 97
Biomarkers of response to immune checkpoint blockade in cancer treatment
Fujii, T., Naing, A., Rolfo, C. D., & Hajjar, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.010 · Cited by 81
Fässler, M., Diem, S., Mangana, J., Ali, O. H., Berner, F., Bomze, D., Ring, S. S., Niederer, R., Gil‐Cruz, C., Perez‐Shibayama, C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0523-2 · Cited by 81
Zimmer, L., Eigentler, T. K., Kiecker, F., Simon, J., Utikal, J., Mohr, P., Berking, C., Kämpgen, E., Dippel, E., Stadler, R., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0716-5 · Cited by 74
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
Jessurun, C. A. C., Vos, J. A. M., Limpens, J., & Luiten, R. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00233 · Cited by 82
Tallerico, R., Cristiani, C. M., Staaf, E., Garofalo, C., Sottile, R., Capone, M., de Coaña, Y. P., Madonna, G., Palella, E., Wolodarski, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1261242 · Cited by 73
Self-citationPulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 75
van Rossum, P. S. N., Deng, W., Routman, D. M., Liu, A. Y., Cai, X., Shiraishi, Y., Peters, M., Merrell, K. W., Hallemeier, C. L., Mohan, R., et al. (2019) · Practical Radiation Oncology · doi:10.1016/j.prro.2019.07.010 · Cited by 72
Bruserud, Ø., Aarstad, H. H., & Tvedt, T. H. A. (2020) · Cancers · doi:10.3390/cancers12071966 · Cited by 79
Prognostic score for patients with advanced melanoma treated with ipilimumab
Diem, S., Kasenda, B., Martín-Liberal, J., Lee, A. T. J., Chauhan, D., Gore, M. E., & Larkin, J. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.007 · Cited by 71
Melanoma Immunotherapy: Next-Generation Biomarkers
Hogan, S. A., Levesque, M. P., & Cheng, P. F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00178 · Cited by 74
Campian, J. L., Piotrowski, A., Ye, X., Hakim, F. T., Rose, J. J., Yan, X.-Y., Lu, Y., Gress, R. E., & Grossman, S. A. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2580-z · Cited by 66
Rossi, S., Toschi, L., Castello, A., Grizzi, F., Mansi, L., & Lopci, E. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3802-5 · Cited by 69
Banna, G. L., Signorelli, D., Metro, G., Galetta, D., Toma, A. D., Cantale, O., Banini, M., Friedlaender, A., Pizzutilo, P., Garassino, M. C., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-583 · Cited by 64
Banna, G. L., Cortellini, A., Cortinovis, D. L., Tiseo, M., Aerts, J. G. J. V., Barbieri, F., Giusti, R., Bria, E., Grossi, F., Pizzutilo, P., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100078 · Cited by 66
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 69
Damuzzo, V., Solito, S., Pinton, L., Carrozzo, E., Valpione, S., Pigozzo, J., Arboretti, R., Chiarion‐Sileni, V., & Mandruzzato, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1249559 · Cited by 65
Pedersen, M., Andersen, R. S., Nørgaard, P. H., Jacobsen, S., Thielsen, P., Straten, P. T., & Svane, I. M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1607-y · Cited by 58
Use of LDH and Autoimmune Side Effects to Predict Response to Ipilimumab Treatment
Dick, J., Lang, N., Slynko, A., Kopp-Schneider, A., Schulz, C., Dimitrakopoulou-Strauss, A., Enk, A., & Hassel, J. (2016) · Immunotherapy · doi:10.2217/imt-2016-0083 · Cited by 58
Yoshino, K., Nakayama, T., Ito, A., Sato, E., & Kitano, S. (2019) · BMC Cancer · doi:10.1186/s12885-019-6138-7 · Cited by 57
Turning the Tide Against Regulatory T Cells
Han, S., Toker, A., Liu, Z. Q., & Ohashi, P. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00279 · Cited by 60
Madonna, G., Ballesteros-Merino, C., Feng, Z., Bifulco, C., Capone, M., Giannarelli, D., Mallardo, D., Simeone, E., Grimaldi, A. M., Caracò, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1405206 · Cited by 55
Self-citationLima, J. P. D. S. N., Georgieva, M., Haaland, B. A., & Lopes, G. D. L., Jr. (2017) · Cancer Medicine · doi:10.1002/cam4.1001 · Cited by 59
Ahmad, S. S., Qian, W., Ellis, S. G., Mason, E. F., Khattak, M. A., Gupta, A., Shaw, H. M., Quinton, A., Kovarikova, J., Thillai, K., et al. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000185 · Cited by 53
Ascierto, P. A., Atkins, M. B., Bifulco, C. B., Botti, G., Cochran, A. J., Davies, M. A., Demaria, S., Dummer, R., Ferrone, S., Formenti, S. C., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0736-1 · Cited by 53
Self-citationYao, L., Jia, G., Lu, L., Bao, Y., & Ma, W. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106628 · Cited by 55
Murakami, S., Shibaki, R., Matsumoto, Y., Yoshida, T., Goto, Y., Kanda, S., Horinouchi, H., Fujiwara, Y., Yamamoto, N., & Ohe, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13721 · Cited by 51
Valpione, S., Martinoli, C., Fava, P., D, S. M. M., Campana, L. G., Quaglino, P., Ferrucci, P. F., Pigozzo, J., Astrua, C., Testori, A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.130 · Cited by 53
Koguchi, Y., Hoen, H. M., Bambina, S., Rynning, M. D., Fuerstenberg, R. K., Curti, B. D., Urba, W. J., Milburn, C. M., Bahjat, F. R., Korman, A. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2303 · Cited by 59
Wang, X., Zhang, B., Chen, X., Mo, H., Wu, D., Lan, B., Li, Q., Xu, B., & Huang, J. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13083 · Cited by 52
Novel Biomarkers for Personalized Cancer Immunotherapy
Shindo, Y., Hazama, S., Tsunedomi, R., Suzuki, N., & Nagano, H. (2019) · Cancers · doi:10.3390/cancers11091223 · Cited by 52
Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma
Lino-Silva, L. S., Salcedo‐Hernández, R. A., García-Pérez, L., Meneses-García, A., & Zepeda‐Najar, C. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000333 · Cited by 48
Hatziioannou, A., Alissafi, T., & Verginis, P. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-493r · Cited by 47
Emerging Biomarkers in Cutaneous Melanoma
Eisenstein, A. S., Gonzalez, E. C., Raghunathan, R., Xu, X., Wu, M., McLean, E. O., McGee, J. S., Ryu, B., & Alani, R. M. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0318-z · Cited by 52
Duan, J., Wang, Y., & Jiao, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1722 · Cited by 51
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Nyakas, M., Aamdal, E., Jacobsen, K. D., Guren, T. K., Aamdal, S., Thorin‐Hagene, K., Brunsvig, P. F., Yndestad, A., Halvorsen, B. L., Taskén, K. A., et al. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13283 · Cited by 47
Chasset, F., Pagès, C., Biard, L., Roux, J., Sidina, I., Madelaine, I., Basset‐Séguin, N., Viguier, M. A., Madjlessi-Ezra, N., Schneider, P., et al. (2015) · European Journal of Dermatology · doi:10.1684/ejd.2014.2471 · Cited by 45
Current status and future perspectives of immunotherapy in bladder cancer treatment
Wu, Z., Liu, J., Dai, R., & Wu, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1768-y · Cited by 53
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition
Friedman, C. F., & Postow, M. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0509-x · Cited by 46
Basler, L., Andratschke, N. H., Ehrbar, S., Gückenberger, M., & Tanadini‐Lang, S. (2018) · Radiation Oncology · doi:10.1186/s13014-018-0952-y · Cited by 44
Zhuo, M., Chen, H., Zhang, T., Yang, X., Zhong, J., Wang, Y., An, T., Wu, M., Wang, Z., Huang, J., et al. (2018) · Cancer Biomarkers · doi:10.3233/cbm-171089 · Cited by 44
Xie, X., Liu, J., Yang, H., Chen, H., Zhou, S., Lin, H., Liao, Z., Ding, Y., Ling, L., & Wang, X. (2019) · Cancer Investigation · doi:10.1080/07357907.2019.1639057 · Cited by 44
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 46
Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma
Hwang, S. J. E., Carlos, G., Wakade, D., Sharma, R. N., & Fernández‐Peñas, P. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000261 · Cited by 41
Metadata
- Authors
- Simeone, E., Gentilcore, G., Giannarelli, D., Grimaldi, A. M., Caracò, C., Curvietto, M., Esposito, A., Paone, M., Palla, M., Cavalcanti, E., Sandomenico, F., Petrillo, A., Botti, G., Fulciniti, F., Palmieri, G., Queirolo, P., Marchetti, P., Ferraresi, V., Rinaldi, G., Pistillo, M. P., Ciliberto, G., Mozzillo, N., & Ascierto, P. A.
- Affiliations
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Instituto Nazionale Tumori Regina Elena (IT)
- National Research Council (IT)
- Ospedale Policlinico San Martino (IT)
- Istituto Dermopatico dell'Immacolata (IT)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Corresponding author
- Ascierto, Paolo A.
- ORCID
- Simeone, Ester
- Gentilcore, Giusy
- Giannarelli, Diana
- Grimaldi, Antonio M.
- Caracò, Corrado
- Curvietto, Marcello
- Esposito, Assunta
- Paone, Miriam
- Palla, Marco
- Cavalcanti, Ernesta
- Sandomenico, Fabio
- Petrillo, Antonella
- Botti, Gerardo
- Fulciniti, Franco
- Palmieri, Giuseppe
- Queirolo, Paola
- Marchetti, Paolo
- Ferraresi, Virginia
- Pistillo, Maria Pia
- Ciliberto, Gennaro
- Ascierto, Paolo A.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2014-04-03
- Volume
- 63
- Issue
- 7
- Pages
- 675-683
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11028686
- OpenAlex
- W1965215390
- Cited by
- 253
- References
- 32
- Citations by year
- 2025: 8 · 2024: 4 · 2023: 11 · 2022: 15 · 2021: 27 · 2020: 38 · 2019: 38 · 2018: 27 · 2017: 25 · 2016: 29 · 2015: 21 · 2014: 8
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-09-25)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, metastatic melanoma, immune checkpoint inhibitors, predictive biomarkers, immune-related adverse events, regulatory T cells, Foxp3, lactate dehydrogenase, C-reactive protein, lymphocyte count, disease control rate, overall survival, immune-related response criteria
- MeSH terms
- Ipilimumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Eye Neoplasms, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Analysis, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.